Search

ImmusanT Gets $40M From Arch, Vatera to Continue Celiac Vaccine Quest

IMMUSANT GETS $40M FROM ARCH, VATERA TO CONTINUE CELIAC VACCINE QUEST

ImmusanT has spent years developing an immunotherapy meant to help people with celiac disease tolerate gluten. Today, on the verge...

LONGTIME CELGENE R&D EXEC TO HELM IMMUNOMEDICS

The company also announced that Brendan Delaney has been appointed CCO, effective today.

 
 
 
Bio Roundup: CBO's Praise, Celgene's Shock, Trump's Opioid Plan & More

BIO ROUNDUP: CBO'S PRAISE, CELGENE'S SHOCK, TRUMP'S OPIOID PLAN & MORE

The White House and the FDA turned the spotlight on the nation's opioid crisis. Blockbuster drugs from Alexion and Tesaro gained expanded...

Traders were blindsided by Celgene's massive earnings flop

TRADERS WERE BLINDSIDED BY CELGENE'S MASSIVE EARNINGS FLOP

Celgene turned in a brutal third-quarter earnings report, missing revenue forecasts and cutting its long-term profit outlook. Traders...

 
 
 
Bio Roundup: Nobel Pursuit, Fundraising Fruit, A Rhythmic IPO & More

BIO ROUNDUP: NOBEL PURSUIT, FUNDRAISING FRUIT, A RHYTHMIC IPO & MORE

The 2017 Nobel Prizes with a biomedical bent were announced this week. Three researchers shared the physiology and medicine prize for...

 
 
 

CELGENE CUDDLES UP WITH ANOTHER CAMBRIDGE BIOTECH, THIS TIME TO TACKLE AUTOIMMUNE DISEASES

Life Sciences Jobs ...

 
 
 
Ex-Cubist CEO Bonney Emerges at Kaleido, Flagship's Latest Microbiome Startup

EX-CUBIST CEO BONNEY EMERGES AT KALEIDO, FLAGSHIP'S LATEST MICROBIOME STARTUP

Flagship Pioneering has been as active as any venture firm at funneling its investment dollars into microbiome drug developers. It's...

After Biogen Deal Fizzles, Rodin Bags $27M And Heads To First Trial

AFTER BIOGEN DEAL FIZZLES, RODIN BAGS $27M AND HEADS TO FIRST TRIAL

An option-to-buy deal, when one company agrees to buy another on prearranged terms after a series of milestones are met, doesn't always...

 
 
 
Immunotherapy Safety Worries Halt Celgene Myeloma Study, Slow 5 Others

IMMUNOTHERAPY SAFETY WORRIES HALT CELGENE MYELOMA STUDY, SLOW 5 OTHERS

Amid growing concerns about the safety of a new class of cancer immunotherapy drugs when combined with other therapies to treat blood...

 
 
 
Celgene Broadens Forma Deal, Adding $195M More for Drug R&D

CELGENE BROADENS FORMA DEAL, ADDING $195M MORE FOR DRUG R&D

Celgene and Forma Therapeutics are expanding their already extensive relationship. The Summit, NJ-based drugmaker has exercised a $195...

 
 
 
 
 
 
 
 
 
Invenra Signs On With Merck in Antibody Discovery Partnership

INVENRA SIGNS ON WITH MERCK IN ANTIBODY DISCOVERY PARTNERSHIP

Invenra has had success developing therapeutic antibodies for its own drug research, and for the research of others. Now the Madison,...

Eli Lilly Pays Nektar $150M Up Front For Autoimmune Drug Rights

ELI LILLY PAYS NEKTAR $150M UP FRONT FOR AUTOIMMUNE DRUG RIGHTS

Nektar Therapeutics has been buoyed of late by the progress of a potential pain drug, but another, much earlier program has caught...